Welcome to licensed pharmacies in Poland:
Non-prescription medicines delivery across Europe.
Frequently ordered: potency boosters (sildenafil OTC), quit smoking aids.
Which is better for weight loss Ozempic (or Wegovy) or Mounjaro?
Which is better for weight loss Ozempic (or Wegovy) or Mounjaro?
* required field
* required field
Other messages will not be sent.
Suggested Products
Space for your product
Angelika Talar-Śpionek Pharmacist, Editor
2 months ago
Due to the insufficient number of clinical trials, it is not possible to objectively compare the effectiveness of Wegovy and Mounjaro drugs in the treatment of obesity at this time.
The mechanism of action of tirzepatide (the active substance in Mounjaro) has not been sufficiently studied. Further studies are needed to be able to draw unequivocal conclusions and determine whether its additional effect on GIP receptors has a significant impact on the effectiveness of therapy.
According to current standards and guidelines of experts – the purpose of obesity treatment is to improve the health and functioning of a person suffering from obesity, prevent the development of complications or their treatment. According to the 2024 recommendations of the Polish Society for the Treatment of Obesity, weight loss is only one of the desired effects of therapy: "However, it should be borne in mind that success in the treatment of obesity is primarily about improving the health, functioning and quality of life of the patient, and not just about reducing excessive body weight."
Therefore, studies should be conducted on a large scale and include not only the effect of the drug on weight loss, but also the aspect of lifestyle changes.
Angelika Talar-Śpionek Pharmacist, Editor
17 months ago
As research shows, due to its complex mechanism of action, tirzepatide (Mounjaro) is supposed to be more effective than the popular and widely used semaglutide (Wegovy).
Tirzepatide treatment has been shown to be associated with clinically significant and sustained (up to 72 weeks) weight reduction compared to placebo. The mean weight loss at week 72 of tirzepatide 10 mg and 15 mg was confirmed to be 12.8 and 14.7 mg, respectively, compared to 3.2% for placebo. At least a 5% decrease was achieved by about 80% of patients in the study groups. The most common adverse reactions included nausea, diarrhoea and vomiting already known from previous studies, and were predominantly mild to moderate, with few events leading to treatment discontinuation.
For the semaglutide injections, the average weight loss after 16 weeks was about 6.4% at a dose of 0.5 mg and about 8.6% at a dose of 1.0 mg of the drug.
Since, in addition to acting on GLP-1 receptors (Ozempic, Wegovy works on them), tirzepatide (Mounjaro) also acts on GIP receptors - it may prove to be more effective.
As research shows, Tirzepatide allows for a statistically significant reduction in body weight and fat content in the body without affecting the composition of muscle tissue.
It has been shown that during clinical trials of tirzepatide lasting 72 weeks (1.5 years), a weight loss of more than 5 kg more was observed compared to the semaglutide group.
Ozempic is not a drug approved for patients with obesity to lose weight. More here:
Here you can check the availability of Mounjaro and Wegovy in pharmacies and make a reservation:
https://www.gdziepolek.pl/produkty/118410/mounjaro-iniekcja/apteki
https://www.gdziepolek.pl/produkty/115667/wegovy-iniekcja/apteki
I've attached links to helpful posts:
